Quantcast

Latest Dendreon Stories

2011-03-22 15:15:00

NEW YORK, March 22, 2011 /PRNewswire/ -- A study in the prostate cancer space completed this week by ITG's Majestic Market Research reveals that Amgen's (Nasdaq: AMGN) Xgeva (a.k.a. denosumab, Prolia) is on track to achieve its blockbuster sales potential and is already stealing share from the leading agent for skeletal related events, Novartis' (NYSE: NVS) Zometa. As for Dendreon's (Nasdaq: DNDN) Provenge, the first FDA-approved therapeutic cancer vaccine, physicians are still clouded...

2011-03-10 13:17:00

SEATTLE, March 10, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the U.S. Food and Drug Administration (FDA) approved the remainder of its New Jersey manufacturing facility, allowing the company to significantly increase the availability of PROVENGE® (sipuleucel-T) to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Last April, upon receiving...

2011-03-01 14:00:00

SEATTLE, March 1, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2010. Revenue for the year ended December 31, 2010 was $48.1 million compared to $0.1 million for the year ended December 31, 2009. Revenue for the fourth quarter of 2010 was $25.0 million compared to $21,000 for the quarter ended December 31, 2009. The net loss for the year ended December 31, 2010 was $439.5 million, or $3.18 per share, compared...

2011-03-01 08:00:00

HONG KONG, March 1 /PRNewswire/ - Today, www.WorldStreetFundamentals.com released its industry report highlighting Dendreon Corp. (NASDAQ: DNDN) and Human Genome Sciences, Inc. (NASDAQ: HGSI). Investors from around the world are invited to view fundamental and technical analysis at www.WorldStreetFundamentals.com. Biotech is enabling creation of new drugs at a faster pace than the traditional pharmaceutical model and some believe that after a decade of mediocre performance it is...

2011-02-24 05:00:00

SEATTLE, Feb. 24, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences: Citi Global Health Care Conference, New York, NY on March 2, 2011 at 2:30 p.m. ET RBC Capital Markets' Healthcare Conference, New York, NY on March 3, 2011 at 11:30 a.m. ET Cowen Annual Healthcare Conference, Boston, MA on March 8, 2011 at 11:00 a.m. ET Roth Orange County Growth Stock Conference, Dana Point, CA on March 14, 2011 at 10:00...

2011-02-17 15:50:00

SEATTLE, Feb. 17, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the 2011 Genitourinary Cancers Symposium annual meeting in Orlando, Florida. "Subsequent Treatment with APC8015F May Have Prolonged Survival of the Control Arm in Phase 3 Sipuleucel-T Studies," abstract #139. Reception and General Poster Session B: Prostate Cancer (A33) from 4:50 to 6:20 p.m. ET on Thursday, February 17, 2011. "Characterization of...

2011-02-08 10:47:00

MIAMI BEACH, Fla., Feb. 8, 2011 /PRNewswire-USNewswire/ -- The Mount Sinai Comprehensive Cancer Center in Miami Beach, Florida is one of only 50 sites throughout the country and, currently, the ONLY site in South Florida to treat advanced prostate cancer patients with a new cellular immunotherapy treatment called PROVENGE®, the first in a new therapeutic class known as autologous cellular immunotherapies. Provenge was recently approved by the U.S. Food and Drug...

2011-02-08 05:00:00

SEATTLE, Feb. 8, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Tuesday, March 1, 2011 at 4:30 p.m. ET to review fourth quarter and year-end financial results. Access to the discussion may be obtained as follows: Time: 4:30 PM ET / 1:30 PM PT Date: March 1, 2011 1-877-548-9590 (domestic) or +1-720-545-0037 Dial-in: (international); conference pass code: 42044580...

2011-02-03 08:31:00

SEATTLE, Feb. 3, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the underwriter in its previously announced public offering of 2.875% convertible senior notes due January 15, 2016 (the "Notes") exercised and closed on its overallotment option in full to purchase an additional $80 million aggregate principal amount of Notes. The sale of the Notes, including the exercise of the overallotment option, resulted in net proceeds to Dendreon of approximately $607.2...

2011-02-03 08:00:00

WORCESTER, Mass., Feb. 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related